Biogen Inc  

(Public, NASDAQ:BIIB)   Watch this stock  
Find more results for biib
+2.11 (0.86%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 242.07 - 249.20
52 week 242.07 - 480.18
Open 248.78
Vol / Avg. 2.12M/2.20M
Mkt cap 52.54B
P/E 16.11
Div/yield     -
EPS 15.34
Shares 218.67M
Beta 0.96
Inst. own 91%
Apr 22, 2016
Q1 2016 Biogen Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Feb 11, 2016
Biogen Inc at Leerink Partners Global Healthcare Conference
Jan 27, 2016
Q4 2015 Biogen Inc Earnings Release
Jan 27, 2016
Q4 2015 Biogen Inc Earnings Call
Jan 11, 2016
Biogen Inc at JPMorgan Healthcare Conference - Q&A Session
Jan 11, 2016
Biogen Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 29.18% 33.50%
Operating margin 41.14% 45.44%
EBITD margin - 52.17%
Return on average assets 16.52% 21.32%
Return on average equity 33.44% 35.15%
Employees 7,350 -
CDP Score - 81 C


225 Binney St
CAMBRIDGE, MA 02142-1031
United States - Map
+1-781-4642000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
About Company - Wikipedia


Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Company's marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, FAMPYRA for multiple sclerosis (MS), ALPROLIX for hemophilia B, and ELOCTATE for hemophilia A, among others. It also collaborates on the development and commercialization of RITUXAN (rituximab), which is a monoclonal antibody for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA, which is for the treatment of chronic lymphocytic leukemia.

Officers and directors

Stelios B. Papadopoulos Ph.D. Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
George A. Scangos Ph.D. Chief Executive Officer, Director
Age: 67
Bio & Compensation  - Reuters
Paul J. Clancy Chief Financial Officer, Executive Vice President - Finance
Age: 54
Bio & Compensation  - Reuters
Kenneth A. Di Pietro Executive Vice President - Human Resources
Age: 57
Bio & Compensation  - Reuters
Susan H. Alexander Esq. Executive Vice President, Chief Legal Officer and Corporate Secretary
Age: 59
Bio & Compensation  - Reuters
John G. Cox Executive Vice President - Global Commercial Operations
Age: 53
Bio & Compensation  - Reuters
Steven H. Holtzman Executive Vice President - Corporate Development
Age: 62
Bio & Compensation  - Reuters
Adriana Karaboutis Executive Vice President - Technology , Business Solutions and Corporate Affairs
Age: 53
Bio & Compensation  - Reuters
Adam M. Koppel M.D., Ph.D. Executive Vice President - Strategy and Business Development
Age: 46
Bio & Compensation  - Reuters
Alfred W. Sandrock Jr., M.D., Ph.D. Executive Vice President - Neurology Discovery and Development and Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters